Figures computed from official regulatory filings — .
Analysttarget 144.55 USD (+20%) · consensus 4.27/5 · 9 buy · 2 hold · 0 sell
Ownershipinsiders 3.32% · institutions 105.49% · short 9.3% of float · 5.01d to cover
In USD · as of Nov 16, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for HAEMONETICS CORP only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.
Market information source · Nov 16, 2026
SEC company identity · Nov 16, 2026
Purchases and sales · full history
202 buys744 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Maunsell Farris Maryanne | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| Maunsell Farris Maryanne | Other | $208.8K | Unusual size | SEC | |
| Maunsell Farris Maryanne | Exercise | $95.2K | SEC | ||
| Maunsell Farris Maryanne | Exercise | $61.7K | SEC | ||
| Maunsell Farris Maryanne | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| Maunsell Farris Maryanne | Exercise | $30.4K | SEC | ||
| Maunsell Farris Maryanne | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| Maunsell Farris Maryanne | Sell | $101.1K | SEC | ||
| Galvin Roy | Other | $17.5K | SEC | ||
| Zane Ellen M | Award | n/a (No price was disclosed in the filing) | SEC | ||
| Madaus Martin Dtrack record | Award | n/a (No price was disclosed in the filing) | SEC | ||
| Bryant Diane M | Award | n/a (No price was disclosed in the filing) | SEC | ||
| ABERNATHY ROBERT Etrack record | Award | n/a (No price was disclosed in the filing) | SEC | ||
| COYLE MICHAEL J | Award | n/a (No price was disclosed in the filing) | SEC | ||
| Johnson Lloyd Emerson | Award | n/a (No price was disclosed in the filing) | SEC | ||
| KROLL MARK W | Award | n/a (No price was disclosed in the filing) | SEC | ||
| Pomeroy Claire | Award | n/a (No price was disclosed in the filing) | SEC | ||
| Miller Laurie A. | Other | $22.3K | SEC | ||
| Maunsell Farris Maryanne | Other | $18.5K | Unusual size | SEC | |
| DArecca James | Other | $141K | SEC | ||
| Galvin Roy | Award | n/a (No price was disclosed in the filing) | SEC | ||
| Chan Frank | Award | n/a (No price was disclosed in the filing) | SEC | ||
| Galvin Roy | Other | $49.5K | Unusual size | SEC | |
| Maunsell Farris Maryanne | Award | n/a (No price was disclosed in the filing) | SEC | ||
| Maunsell Farris Maryanne | Other | $11.1K | Unusual size | SEC |